Your skin microbiome is already producing compounds that support well aging

The skincare industry has spent a long time selling the idea that bacteria on your face are the enemy. Antibacterial cleansers, sterilizing toners, the whole vocabulary of purifying and detoxifying.

The biology says something close to the opposite. Some of the most useful chemistry happening on your skin is not being produced by your skin. It is being produced by the organisms living on it, and they were doing it before you bought anything.

Your bacteria make an antioxidant

Start with the most striking example.

Cutibacterium acnes, the organism with the worst public reputation of anything on human skin, secretes a protein called RoxP, short for radical oxygenase. It has strong antioxidant activity, and it is not a laboratory curiosity. RoxP protects human keratinocytes and monocytes from oxidative damage, measurably improving cell viability under oxidative stress.¹

The more interesting finding is what happens when it is absent. In skin affected by oxidative disease, RoxP concentration declines in step. Patients with actinic keratosis showed lower RoxP in affected areas than in their own healthy skin.¹

Sit with the implication. Oxidative stress is one of the central mechanisms of skin aging, and the entire antioxidant category in skincare exists to address it. Meanwhile a bacterium named after acne has been secreting an antioxidant protein onto your face for your whole life, free of charge.

And they build your barrier

The second example is structural rather than chemical.

Ceramides are the lipids that hold the outermost layer of skin together and keep water in. They are the reason barrier repair moisturizers list them on the front of the box. Your skin makes its own, and it turns out that is not the whole supply.

Commensal Staphylococcus epidermidis generates ceramides that contribute directly to skin barrier homeostasis.² A resident bacterium is manufacturing a component of your barrier for you.

Put the two findings together and the picture inverts. This is not a population to be suppressed. It is a working part of the organ.

Which is why sterilizing your face backfires

Patients arrive constantly with skin that has been stripped. Foaming cleansers twice daily, alcohol toners, benzoyl peroxide used as a face wash, sometimes an antibacterial soap. The skin is tight, reactive, and paradoxically breaking out more than when they started.

A reasonable reading is that they have spent months reducing the population that makes their antioxidant and part of their barrier lipid. The response looks like sensitivity, and sensitivity is what happens when a barrier stops working.

This is not an argument against treating acne, which is a real condition requiring real treatment. It is an argument against treating bacteria as the target when the actual issue is which organisms are present and in what balance.

Your baseline is not universal

Here is the part most microbiome content skips, and the reason I am careful about generic advice.

Skin microbial communities differ measurably between populations. A study comparing 200 samples from Chinese individuals against datasets from the United States, Tanzania and mainland China found race-based clustering in both community membership and structure, with differing abundances of Propionibacterium, Corynebacterium, Staphylococcus and Enhydrobacter.³

The authors drew the conclusion that matters: interventions attempting to improve health by altering the microbiome may not be effective across different population groups.³

So a protocol built on what is normal for one population may be aiming at the wrong target for another. This is the same problem that runs through device selection and through skin typing, appearing again one layer down. Measuring your own baseline is more useful than inheriting somebody else's.

What a swab actually gives you

Sequencing a skin swab returns a description of what is growing on you: which organisms, in what proportion, with derived measures such as diversity and a classification of microbiome type.⁴

That is more than a category and less than a diagnosis, and both halves are useful. It replaces an assumption about what your skin is probably doing with a reading of what it is actually doing. Composition shifts with body site, season, recent products and what you washed with that morning, so one result is a reading rather than a verdict, and the informative pattern usually appears when you measure again after changing something. The links between specific compositions and specific outcomes are still largely associative, which is why the result belongs in a plan rather than being the plan.

One distinction worth making, because both tests sequence DNA and the names run together: this reads the genes of the organisms on your skin, not your own. A genetic skin test reads your genome, which is fixed, is read once, and describes tendency. A swab describes what is present now and what it is producing, which is what makes it worth repeating after you change something.

Where it earns its place is when the obvious answer has already failed. Persistent inflammatory conditions that have not responded to reasonable treatment. Recurrent acne with a pattern that does not fit. A barrier wrecked by an aggressive routine, where the useful question is what to stop rather than what to add.

Removing one strain without removing the rest

Here is where the argument of this article turns into a treatment.

If your resident organisms are producing an antioxidant and part of your barrier lipid, then anything that clears bacteria broadly is going to cost you something. That is the trouble with antibiotics in skin, and with the sterilizing routines people put themselves on. They do not distinguish. The strain driving inflammation and the strain making RoxP go together.

Bacteriophages do distinguish. They are viruses that infect bacteria, and they are extraordinarily specific, recognizing particular strains rather than whole species. They kill by lysis rather than by slowing growth. Unlike broad-spectrum antibiotics, which act across many species, phages recognize and infect their target organism, which reduces collateral damage to the rest of the microbiome.⁵

The practical version: you can remove the strains driving the problem and leave the ones doing you favors.

The early data supports the mechanism. In a mouse model of C. acnes induced acne-like lesions, topical phage in a gel reduced lesion diameter, elevation and bacterial load, and sharply reduced neutrophil infiltration along with inflammatory signals including IL-6, TNF-alpha and IL-17. The phages penetrated intact skin and stayed viable at the lesion.⁶

On safety, the mechanism is the reassurance. Phages target bacteria, not human cells, which is what allows them to be aimed at a strain without acting on you. They are also not exotic: phages are among the most abundant biological entities on earth and are already present on your skin. Across clinical studies, serious adverse events have been extremely rare, and reported effects mild and transient.⁷

I did not come to this from the outside. I spent years working with this technology, and what convinced me was watching it work: skin that had not responded to the usual sequence of treatments improving on a preparation built for what was actually growing on it.

The published human literature is still building, and much of what exists comes from animal models and in vitro work.⁵ That is a statement about how much has been formally trialled, not about whether it is safe to use.

How we use it

Microbiome analysis is offered where it is likely to change the plan, not as a default add-on. Sequencing identifies what is actually present; where a targeted phage preparation is appropriate, it is formulated from that result rather than from a category.

Frequently the most useful output is subtraction. When someone learns their skin is doing more for them than their cabinet of products is, the plan gets shorter.

We use Parallel Health for microbiome sequencing and phage formulation.

Disclosure: I was previously an executive at Parallel Health and am now an investor in the company. I invested after working with the science, not before.